In a major shake-up of the federal government’s pandemic preparedness efforts, the U.S. Department of Health and Human Services (HHS) has canceled a $590 million contract with biotechnology company Moderna. The contract was intended to support the development of a messenger RNA (mRNA) vaccine for avian influenza strains that pose a significant threat of causing future pandemics.
Originally awarded in January 2025, the contract was part of a broader push to bolster the country’s biodefense capabilities. Moderna had been developing a vaccine candidate using the same mRNA technology that proved successful during the COVID-19 pandemic. Early-stage clinical trials were already underway, involving several hundred healthy volunteers, with preliminary results showing encouraging immune responses and no major safety concerns.
However, the project has now been brought to an abrupt halt. HHS officials said the decision followed a detailed internal review, which concluded that the program failed to meet the department’s evolving standards for safety, testing rigor, and transparency. The cancellation comes under the leadership of HHS Secretary Robert F. Kennedy Jr., who has previously expressed reservations about mRNA vaccine platforms and has advocated for increased scrutiny of such technologies.
According to the department, the review raised questions about the adequacy of Moderna’s trial design and whether the data gathered so far could support the development of a vaccine suitable for emergency use. Officials also pointed to broader concerns about overreliance on mRNA platforms in pandemic response planning and the need for diversified vaccine technologies to prepare for future threats.
The decision has triggered swift reaction from the public health and scientific communities. Critics argue that halting the project could leave the country vulnerable if avian flu strains—particularly H5N1—begin to spread more widely among humans. While human-to-human transmission of H5N1 remains rare, outbreaks among bird populations have led to spillover infections in mammals and, in some cases, limited human cases. Public health experts warn that pulling back now could delay the availability of a vital tool if such a virus were to mutate and cause a large-scale outbreak.
Moderna, for its part, has expressed disappointment in the decision but reaffirmed its commitment to pandemic preparedness. The company said it will continue pursuing development of its flu vaccine candidate through alternative funding and regulatory pathways. In a statement, Moderna highlighted its ongoing investment in mRNA technologies and emphasized the importance of being ready to respond quickly to novel infectious disease threats.
The cancellation reflects broader tensions between accelerating medical innovation and ensuring robust oversight. Supporters of the decision argue that the federal government must take a more cautious and deliberate approach to public health spending, especially given the rapid pace of development that characterized much of the COVID-19 vaccine rollout. Critics, however, worry that political ideology is playing too large a role in scientific and medical decision-making, potentially putting lives at risk.
This latest move also raises questions about the future direction of U.S. pandemic preparedness. With other vaccine developers also exploring mRNA-based solutions for flu and other infectious diseases, the cancellation could have ripple effects across the biotech sector. It may also influence how other nations approach their own vaccine development partnerships, as the U.S. had previously been seen as a leader in mRNA innovation.
For now, the path forward remains uncertain. HHS has not announced a replacement plan or alternative contract to fill the gap left by the Moderna project. Meanwhile, scientists continue to warn that the next pandemic threat may emerge at any time—and that time is a resource the world can ill afford to waste.
As the debate continues, what remains clear is that the intersection of science, public health policy, and politics will continue to shape how the United States prepares for—and responds to—the pandemics of the future.
